What is GRFS stock price today?

GRFS (Grifols Sa) stock is trading at $8.64 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is GRFS stock going up or down today?

GRFS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy GRFS stock now?

The decision to buy GRFS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is GRFS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for GRFS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is GRFS stock overvalued or undervalued?

GRFS currently trades at a P/E ratio of 13.81, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if GRFS is fairly priced.

What is GRFS's P/E ratio?

GRFS has a price-to-earnings (P/E) ratio of 13.81, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is GRFS's market cap?

GRFS (Grifols Sa) has a market capitalization of $7.65 billion, making it a small-cap stock.

What is GRFS's price to book ratio?

GRFS trades at a price-to-book (P/B) ratio of 1.01, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does GRFS pay dividends?

Yes, GRFS pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is GRFS's dividend yield?

GRFS's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is GRFS stock a good long-term investment?

GRFS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is GRFS's revenue growth rate?

GRFS has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, GRFS is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in GRFS?

Key risks for GRFS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does GRFS compare to its competitors?

Compare GRFS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize GRFS's performance and positioning.

What is GRFS's stock price target for 2026?

Our AI model provides price targets for GRFS based on fundamental analysis: Bull case $11.23 (+30%), Base case $9.94 (+15%), Bear case $7.78 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about GRFS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for GRFS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is GRFS's next earnings report?

GRFS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

GRFS - Grifols Sa

NYSE * Health Care * Pharmaceuticals

$8.64

$-0.25 (-2.81%)

About Grifols Sa

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain.

GRFS Key Statistics

Market Cap

$7.65B

P/E Ratio

13.81

P/B Ratio

1.01

EPS

$0.63

Dividend Yield

0.02%

Revenue Growth

+0.0%

Profit Margin

0.0%

Employees

23,800

How GRFS Compares to Peers

GRFS has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

GRFS is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
GRFS(This stock)	$7.65B	13.8	0%	0.0%	-
AAPLApple Inc	$3.66T	33.8	6%	0.3%	vs AAPL
MSFTMicrosoft Corp	$3.38T	36.3	15%	0.4%	vs MSFT
GOOGLAlphabet Inc	$3.89T	32.6	0%	0.3%	vs GOOGL
AMZNAmazon Com	$2.56T	33.8	0%	0.1%	vs AMZN
NVDANvidia Corp	$4.33T	47.9	114%	0.5%	vs NVDA

Grifols Sa Company Information

Headquarters: New York; U.S.A
Website: www.grifols.com
Sector: Health Care
Industry: Pharmaceuticals

About Grifols Sa

GRFS Key Statistics

How GRFS Compares to Peers

Grifols Sa Company Information

Upcoming Events for GRFS